Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 5:53 pm Sale | 2025-06-30 | 13G | Adagio Medical Holdings, Inc. ADGM | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,200,000 (Position Closed) | Filing History |
| 2025-08-11 4:43 pm Unchanged | 2025-08-07 | 13D | Cidara Therapeutics, Inc. CDTX | RA CAPITAL MANAGEMENT L.P. | 3,365,523 13.300% | 0 (Unchanged) | Filing History |
| 2025-07-25 5:00 pm Purchase | 2025-07-18 | 13G | Contineum Therapeutics, Inc. Class A Common Stock CTNM | RA CAPITAL MANAGEMENT L.P. | 2,122,000 9.900% | 2,122,000 (New Position) | Filing History |
| 2025-06-30 5:05 pm Purchase | 2025-06-26 | 13D | Cidara Therapeutics, Inc. CDTX | RA CAPITAL MANAGEMENT L.P. | 3,365,523 15.800% | 2,272,727 (+207.97%) | Filing History |
| 2025-06-27 4:16 pm Purchase | 2025-06-25 | 13D | Vor Biopharma Inc. VOR | RA CAPITAL MANAGEMENT L.P. | 1,986,993 31.800% | 1,500 (+0.08%) | Filing History |
| 2025-06-06 4:50 pm Purchase | 2025-06-04 | 13D | Tyra Biosciences, Inc. TYRA | RA CAPITAL MANAGEMENT L.P. | 11,899,788 22.400% | 1,214,898 (+11.37%) | Filing History |
| 2025-05-19 5:46 pm Sale | 2025-05-15 | 13D | iTeos Therapeutics, Inc. ITOS | RA CAPITAL MANAGEMENT L.P. | 2,134,806 4.900% | -2,028,470 (-48.72%) | Filing History |
| 2025-05-15 4:59 pm Sale | 2025-03-31 | 13G | Kura Oncology, Inc. KURA | RA CAPITAL MANAGEMENT L.P. | 4,004,610 4.900% | -364,388 (-8.34%) | Filing History |
| 2025-05-15 4:58 pm Purchase | 2025-03-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA CAPITAL MANAGEMENT L.P. | 11,063,125 9.900% | 187,671 (+1.73%) | Filing History |
| 2025-05-15 4:58 pm Purchase | 2025-03-31 | 13G | GH Research PLC GHRS | RA CAPITAL MANAGEMENT L.P. | 6,944,648 11.200% | 257,959 (+3.86%) | Filing History |
| 2025-05-15 4:57 pm Purchase | 2025-03-31 | 13G | Geron Corporation GERN | RA CAPITAL MANAGEMENT L.P. | 63,988,106 9.900% | 668,553 (+1.06%) | Filing History |
| 2025-05-15 4:56 pm Purchase | 2025-03-31 | 13G | Unicycive Therapeutics, Inc. UNCY | RA CAPITAL MANAGEMENT L.P. | 1,328,578 9.900% | 176,566 (+15.33%) | Filing History |
| 2025-05-15 4:56 pm Purchase | 2025-03-31 | 13G | Dyne Therapeutics, Inc. DYN | RA CAPITAL MANAGEMENT L.P. | 9,714,392 8.500% | 3,333,248 (+52.24%) | Filing History |
| 2025-05-15 4:55 pm Purchase | 2025-03-31 | 13G | Surrozen, Inc. SRZN | RA CAPITAL MANAGEMENT L.P. | 867,418 9.900% | 543,756 (+168.00%) | Filing History |
| 2025-05-15 4:55 pm Unchanged | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,866,733 8.900% | 0 (Unchanged) | Filing History |
| 2025-05-15 4:53 pm Sale | 2025-03-31 | 13G | Chimerix, Inc. CMRX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -8,800,000 (Position Closed) | Filing History |
| 2025-05-15 4:53 pm Unchanged | 2025-03-31 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,206,271 7.000% | 0 (Unchanged) | Filing History |
| 2025-05-15 4:52 pm Sale | 2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -4,878,000 (Position Closed) | Filing History |
| 2025-05-15 4:51 pm Purchase | 2025-03-31 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 12,964,491 9.900% | 314,763 (+2.49%) | Filing History |
| 2025-05-15 4:51 pm Sale | 2025-03-31 | 13G | Bright Minds Biosciences Inc. DRUG | RA CAPITAL MANAGEMENT L.P. | 206,427 2.900% | -254,402 (-55.21%) | Filing History |